AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (884.1 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Traditional Chinese medicine-based neurorestorative therapy for Alzheimer’s and Parkinson’s disease

Zhu Zhang1,2,§Shiqing Zhang1,2,§Cathy Nga-Ping Lui1,2Peili Zhu1,2Zhang Zhang1,2Kaili Lin1,2Yiwu Dai3( )Ken Kin-Lam Yung1,2( )
Department of Biology, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China
Golden Meditech Center for NeuroRegeneration Sciences (GMCNS), Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China
Department of Neurosurgery, Bayi Brain Hospital, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China

§ The authors contributed equally to this work

Show Author Information

Abstract

The prevalence of multiple neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), has been dramatically increasing, particularly in the aging population. However, the currently available therapies merely alleviate the symptoms of these diseases and are unable to retard disease progression significantly. Traditional Chinese medicine (TCM) has been used in clinical practice for thousands of years for ameliorating symptoms or interfering with the pathogenesis of aging- associated diseases. Modern pharmacological studies have proved that TCM imparts disease-modifying therapeutic effects against these diseases, such as protection of neurons, clearance of protein aggregates, and regulation of neuroinflammation. This review summarizes the evidence from recent studies on AD and PD therapies regarding the neuroprotective activities and molecular mechanisms of a series of TCM formulations comprising herbs and their active ingredients. The findings of this review support the use of TCM as an alternative source of therapy for the treatment of neurodegenerative diseases.

References

[1]
E De Pablo-Fernández, AJ Lees, JL Holton, et al. Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. JAMA Neurol. 2019, 76(4): 470-479.
[2]
H Zetterberg, JM Schott. Biomarkers for Alzheimer's disease beyond amyloid and tau. Nat Med. 2019, 25(2): 201-203.
[3]
J Hardy, DJ Selkoe. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002, 297(5580): 353-356.
[4]
LM de Lau, MM Breteler. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006, 5(6): 525-535.
[5]
MG Spillantini, RA Crowther, R Jakes, et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 1998, 251(3): 205-208.
[6]
SI Finkel. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin Ther. 2004, 26(7): 980-990.
[7]
JH Lee, SK Jeong, BC Kim, et al. Donepezil across the spectrum of Alzheimer’s disease: dose optimization and clinical relevance. Acta Neurol Scand. 2015, 131(5): 259-267.
[8]
MF Bastide, WG Meissner, B Picconi, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015, 132: 96-168.
[9]
U Bonuccelli, A Colzi, P Del Dotto. Pergolide in the treatment of patients with early and advanced Parkinson’s disease. Clin Neuropharmacol. 2002, 25(1): 1-10.
[10]
WD Le, J Jankovic. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001, 18(6): 389-396.
[11]
J Still. Use of animal products in traditional Chinese medicine: environmental impact and health hazards. Complement Ther Med. 2003, 11(2): 118-122.
[12]
TY Wu, CP Chen, CP Chen, et al. Traditional Chinese medicines and Alzheimer’s disease. Taiwan J Obstet Gynecol. 2011, 50(2): 131-135.
[13]
M Pallàs, D Porquet, A Vicente, et al. Resveratrol: new avenues for a natural compound in neuroprotection. Curr Pharm Des. 2013, 19(38): 6726-6731.
[14]
A Tachjian, V Maria, A Jahangir. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010, 55(6): 515-525.
[15]
AL Hopkins. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008, 4(11): 682-690.
[16]
I Solanki, P Parihar, MS Parihar. Neurodegenerative diseases: From available treatments to prospective herbal therapy. Neurochem Int. 2016, 95: 100-108.
[17]
SY Gao, JW Lin, TQ Wang, et al. Qingxin Kaiqiao Fang ameliorates memory impairment and inhibits apoptosis in APP/PS1 double transgenic mice through the MAPK pathway. Drug Des Devel Ther. 2019, 13: 459-475.
[18]
GW Gong, BH Qi, YT Liang, et al. Danggui Buxue Tang, an ancient Chinese herbal decoction, protects β-amyloid-induced cell death in cultured cortical neurons. BMC Complement Altern Med. 2019, 19(1): 9.
[19]
R Shi, SS Zhang, GQ Cheng, et al. Ginsenoside Rg1 and acori graminei rhizoma attenuates neuron cell apoptosis by promoting the expression of miR-873-5p in Alzheimer’s disease. Neurochem Res. 2018, 43(8): 1529-1538.
[20]
YS Mo, EJ Xu, RR Wei, et al. Bushen-yizhi formula alleviates neuroinflammation via inhibiting NLRP3 inflammasome activation in a mouse model of Parkinson’s disease. Evid Based Complement Alternat Med. 2018, 2018: 3571604.
[21]
RR Wei, J OuYang, WX Lin, et al. Curative anti- inflammatory properties of Chinese optimized yinxieling formula in models of Parkinson's disease. Evid Based Complement Alternat Med. 2018, 2018: 6142065.
[22]
XX Bao, HH Ma, H Ding, et al. Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson’s disease. J Integr Med. 2018, 16(4): 290-296.
[23]
ZG Li, KYC Lam, XY Liu, et al. A Chinese herbal preparation, Xiao-Er-An-Shen decoction, exerts neuron protection by modulation of differentiation and antioxidant activity in cultured PC12 cells. Evid Based Complement Alternat Med. 2018, 2018: 8670421.
[24]
L Yan, M Wei, AG Gong, et al. A modified Chinese herbal decoction (Kai-Xin-San) promotes NGF-induced neuronal differentiation in PC12 cells via up-regulating trk A signaling. Front Cell Dev Biol. 2017, 5: 118.
[25]
IC Chen, TH Lin, YH Hsieh, et al. Formulated Chinese medicine Shaoyao Gancao Tang reduces tau aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation. Oxid Med Cell Longev. 2018, 2018: 9595741.
[26]
C Cao, JY Xiao, MQ Liu, et al. Active components, derived from Kai-Xin-San, a herbal formula, increase the expressions of neurotrophic factor NGF and BDNF on mouse astrocyte primary cultures via cAMP- dependent signaling pathway. J Ethnopharmacol. 2018, 224: 554-562.
[27]
CY Zhu, QH Xu, ZY Mao, et al. The Chinese medicine Wu-Tou decoction relieves neuropathic pain by inhibiting hippocampal microglia activation. Sci Rep. 2018, 8(1): 12292.
[28]
BS He, FX Xu, TX Yan, et al. Tectochrysin from Alpinia Oxyphylla Miq. alleviates Aβ1-42 induced learning and memory impairments in mice. Eur J Pharmacol. 2019, 842: 365-372.
[29]
Y Qi, XH Cheng, HT Jing, et al. Effect of Alpinia oxyphylla-Schisandra chinensis herb pair on inflammation and apoptosis in Alzheimer’s disease mice model. J Ethnopharmacol. 2019, 237: 28-38.
[30]
YL Wang, MS Wang, KY Fan, et al. Protective effects of Alpinae Oxyphyllae Fructus extracts on lipopolysaccharide-induced animal model of Alzheimer’s disease. J Ethnopharmacol. 2018, 217: 98-106.
[31]
YL Wang, MS Wang, MJ Xu, et al. Nootkatone, a neuroprotective agent from Alpiniae Oxyphyllae Fructus, improves cognitive impairment in lipopolysaccharide- induced mouse model of Alzheimer’s disease. Int Immunopharmacol. 2018, 62: 77-85.
[32]
BS He, FX Xu, F Xiao, et al. Neuroprotective effects of nootkatone from Alpiniae oxyphyllae Fructus against amyloid-β-induced cognitive impairment. Metab Brain Dis. 2018, 33(1): 251-259.
[33]
L Zhou, PP Huang, LL Chen, et al. Panax notoginseng saponins ameliorate Aβ-mediated neurotoxicity in C. Elegans through antioxidant activities. Evid Based Complement Alternat Med. 2019, 2019: 7621043.
[34]
SZ Liu, W Cheng, JW Shao, et al. Notoginseng saponin Rg1 prevents cognitive impairment through modulating APP processing in Aβ1-42-injected rats. Curr Med Sci. 2019, 39(2): 196-203.
[35]
BB Zhang, XL Hu, YY Wang, et al. Neuroprotective effects of dammarane-type saponins from Panax notoginseng on glutamate-induced cell damage in PC12 cells. Planta Med. 2019, 85(9/10): 692-700
[36]
JL Huang, YQ Feng, LR Bai, et al. Fraction n-butanol of Radix notoginseng protects PC12 cells from Aβ25-35- induced cytotoxicity and alleviates cognitive deficits in SAMP8 mice by attenuating oxidative stress and Aβ accumulation. Evid Based Complement Alternat Med. 2017, 2017: 8469754.
[37]
Y Zhang, ZF Pi, FR Song, et al. Ginsenosides attenuate d-galactose- and AlCl3-inducedspatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer’s disease. J Ethnopharmacol. 2016, 194: 188-195.
[38]
EJ Kim, IH Jung, TK van Le, et al. Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. J Ethnopharmacol. 2013, 146(1): 294-299.
[39]
HM Luo, JT Hu, Y Wang, et al. In vivo and in vitro neuroprotective effects of Panax ginseng glycoproteins. Int J Biol Macromol. 2018, 113: 607-615.
[40]
YM Pan, JQ Xu, P Jin, et al. Royal jelly ameliorates behavioral deficits, cholinergic system deficiency, and autonomic nervous dysfunction in ovariectomized cholesterol-fed rabbits. Molecules. 2019, 24(6): E1149.
[41]
YM Pan, JQ Xu, C Chen, et al. Royal jelly reduces cholesterol levels, ameliorates Aβ pathology and enhances neuronal metabolic activities in a rabbit model of Alzheimer’s disease. Front Aging Neurosci. 2018, 10: 50.
[42]
XX Zhang, X Wang, XH Hu, et al. Neuroprotective effects of a Rhodiola crenulata extract on amyloid-β peptides (Aβ1-42)-induced cognitive deficits in rat models of Alzheimer's disease. Phytomedicine. 2019, 57: 331-338.
[43]
H Tang, J Wang, L Zhao, et al. Rhodiola rosea L extract shows protective activity against Alzheimer’s disease in 3xTg-AD mice. Trop J Pharm Res. 2017, 16(3): 509.
[44]
JM Wang, ZQ Qu, JL Wu, et al. Mitochondrial protective and anti-apoptotic effects of Rhodiola crenulata extract on hippocampal neurons in a rat model of Alzheimer’s disease. Neural Regen Res. 2017, 12(12): 2025-2034.
[45]
SC Huang, JX Mao, K Ding, et al. Polysaccharides from Ganoderma lucidum promote cognitive function and neural progenitor proliferation in mouse model of Alzheimer’s disease. Stem Cell Reports. 2017, 8(1): 84-94.
[46]
GX Lai, YR Guo, DL Chen, et al. Alcohol extracts from Ganoderma lucidum delay the progress of Alzheimer’s disease by regulating DNA methylation in rodents. Front Pharmacol. 2019, 10: 272.
[47]
QX Xu, Y Hu, GY Li, et al. Multi-target anti-alzheimer activities of four prenylated compounds from Psoralea fructus. Molecules. 2018, 23(3): E614.
[48]
ZJ Chen, YF Yang, YT Zhang, et al. Dietary total prenylflavonoids from the fruits of Psoralea corylifolia L. prevents age-related cognitive deficits and down- regulates Alzheimer’s markers in SAMP8 mice. Molecules. 2018, 23(1): E196.
[49]
YJ Chiu, CM Lee, TH Lin, et al. Chinese herbal medicine Glycyrrhiza inflata reduces Aβ aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation. Am J Chin Med. 2018, 46(7): 1535-1559.
[50]
YH Ko, SH Kwon, SY Lee, et al. Liquiritigenin ameliorates memory and cognitive impairment through cholinergic and BDNF pathways in the mouse Hippocampus. Arch Pharm Res. 2017, 40(10): 1209-1217.
[51]
PJ Xu, ZG Li, H Wang, et al. Triptolide inhibited cytotoxicity of differentiated PC12 cells induced by amyloid-beta₂₅₋₃₅ via the autophagy pathway. PLoS One. 2015, 10(11): e0142719.
[52]
CQ Ning, LM Mo, XW Chen, et al. Triptolide derivatives as potential multifunctional anti-Alzheimer agents: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett. 2018, 28(4): 689-693.
[53]
K Veerappan, S Natarajan, P Ethiraj, et al. Inhibition of IKKβ by celastrol and its analogues-an in silico and in vitro approach. Pharm Biol. 2017, 55(1): 368-373.
[54]
YR Qin, Y Zhang, I Tomic, et al. Ginkgo biloba extract EGb 761 and its specific components elicit protective protein clearance through the autophagy-lysosomal pathway in tau-transgenic mice and cultured neurons. J Alzheimers Dis. 2018, 65(1): 243-263.
[55]
C Huang, FQ Lin, GQ Wang, et al. Tetrahydroxystilbene glucoside produces neuroprotection against 6-OHDA- induced dopamine neurotoxicity. Oxidative Med Cell Longev. 2018, 2018: 1-9.
[56]
YD Zhu, J Zhu, X Yang, et al. Polygonum multiflorum extracts protect the SH-SY5Y cells against the oxidative stress injury induced by MPP+. Int J Neurorehabilitation Eng. 2016, 3(5): 2376-0281.
[57]
C Yang, YS Mo, EJ Xu, et al. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model. Int Immunopharmacol. 2019, 75: 105651.
[58]
H Gao, LR Dou, L Shan, et al. Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of Radix astragali. Neuroreport. 2018, 29(7): 577-582.
[59]
H Liu, S Chen, CJ Guo, et al. Astragalus polysaccharide protects neurons and stabilizes mitochondrial in a mouse model of parkinson disease. Med Sci Monit. 2018, 24: 5192-5199.
[60]
S Peng, L Xu, JY Ma, et al. Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine. Neural Regen Res. 2018, 13(11): 1981-1987.
[61]
MZ Zheng, CM Liu, YJ Fan, et al. Total glucosides of paeony (TGP) extracted from Radix Paeoniae Alba exerts neuroprotective effects in MPTP-induced experimental Parkinsonism by regulating the cAMP/ PKA/CREB signaling pathway. J Ethnopharmacol. 2019, 245: 112182.
[62]
TT Zhou, MR Zhu, ZH Liang. (-)-Epigallocatechin- 3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease. Mol Med Rep. 2018, 17(4): 4883-4888.
[63]
SM Liu, XZ Li, SN Zhang, et al. Acanthopanax senticosus protects structure and function of mesencephalic mitochondria in a mouse model of Parkinson’s disease. Chin J Integr Med. 2018, 24(11): 835-843.
[64]
ZL Ren, CD Wang, T Wang, et al. Ganoderma lucidum extract ameliorates MPTP-induced Parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis. Acta Pharmacol Sin. 2019, 40(4): 441-450.
[65]
MY Liao, YD Zhao, LZ Huang, et al. Isoliquiritigenin and liquiritin from Glycyrrhiza uralensis inhibit α-synuclein amyloid formation. RSC Adv. 2016, 6(89): 86640-86649.
[66]
GZ Hu, XL Gong, L Wang, et al. Triptolide promotes the clearance of α-synuclein by enhancing autophagy in neuronal cells. Mol Neurobiol. 2017, 54(3): 2361-2372.
[67]
AM Gorman. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008, 12(6A): 2263-2280.
[68]
SG Cho, EJ Choi. Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol. 2002, 35(1): 24-27.
[69]
WW Wong, H Puthalakath. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life. 2008, 60(6): 390-397.
[70]
SQ Feng, J Xiao, FB Han, et al. Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017). J Neurorestoratol. 2018, 6: 65-68.
[71]
S Pinton, T Sampaio, A Savall, et al. Neurotrophic factors in Alzheimer’s and Parkinson’s diseases: implications for pathogenesis and therapy. Neural Regen Res. 2017, 12(4): 549.
[72]
T Zigova, V Pencea, SJ Wiegand, et al. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998, 11(4): 234-245.
[73]
T Kobayashi, H Ahlenius, P Thored, et al. Intracerebral infusion of glial cell line-derived neurotrophic factor promotes striatal neurogenesis after stroke in adult rats. Stroke. 2006, 37(9): 2361-2367.
[74]
A Ghosh, ME Greenberg. Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis. Neuron. 1995, 15(1): 89-103.
[75]
G Acsadi, RA Anguelov, HB Yang, et al. Increased survival and function of SOD1 mice after glial cell- derived neurotrophic factor gene therapy. Hum Gene Ther. 2002, 13(9): 1047-1059.
[76]
LF Kromer. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 1987, 235(4785): 214-216.
[77]
W Fischer, K Wictorin, A Björklund, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987, 329(6134): 65-68.
[78]
KYC Lam, QY Wu, WH Hu, et al. Asarones from Acori Tatarinowii Rhizoma stimulate expression and secretion of neurotrophic factors in cultured astrocytes. Neurosci Lett. 2019, 707: 134308.
[79]
CK Glass, K Saijo, B Winner, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010, 140(6): 918-934.
[80]
T Nagatsu, M Sawada. Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des. 2005, 11(8): 999-1016.
[81]
I Russo, S Barlati, F Bosetti. Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem. 2011, 116(6): 947-956.
[82]
HM Gao, JS Hong. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29(8): 357-365.
[83]
RK Sajja, MA Kaisar, V Vijay, et al. In vitro modulation of redox and metabolism interplay at the brain vascular endothelium: genomic and proteomic profiles of sulforaphane activity. Sci Rep. 2018, 8(1): 12708.
[84]
I Buendia, P Michalska, E Navarro, et al. Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol Ther. 2016, 157: 84-104.
[85]
E Chernykh, E Shevela, M Kafanova, et al. Monocyte- derived macrophages for treatment of cerebral palsy: a study of 57 cases. J Neurorestoratol. 2018, 6: 41-47.
[86]
KYC Lam, P Yao, HY Wang, et al. Asarone from Acori Tatarinowii Rhizome prevents oxidative stress- induced cell injury in cultured astrocytes: a signaling triggered by Akt activation. PLoS One. 2017, 12(6): e0179077.
[87]
B Gargouri, J Carstensen, HS Bhatia, et al. Anti- neuroinflammatory effects of Ginkgo biloba extract EGb761 in LPS-activated primary microglial cells. Phytomedicine. 2018, 44: 45-55.
[88]
Q Cai, YY Li, G Pei. Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response. J Neuroinflammation. 2017, 14(1): 63.
[89]
SY Park, ML Jin, NJ Kang, et al. Anti-inflammatory effects of novel Polygonum multiflorum compound via inhibiting NF-κB/MAPK and upregulating the Nrf2 pathways in LPS-stimulated microglia. Neurosci Lett. 2017, 651: 43-51.
[90]
MY Huang, CE Tu, SC Wang, et al. Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia. BMC Complement Altern Med. 2018, 18(1): 221.
[91]
MM You, YF Chen, YM Pan, et al. Royal jelly attenuates LPS-induced inflammation in BV-2 microglial cells through modulating NF-κB and p38/JNK signaling pathways. Mediators Inflamm. 2018, 2018: 7834381.
[92]
CA Ross, MA Poirier. Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol. 2005, 6(11): 891-898.
[93]
AB Singleton, M Farrer, J Johnson, et al. Alpha- Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302(5646): 841.
[94]
JA Hardy, GA Higgins. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992, 256(5054): 184-185.
[95]
M Komatsu, S Waguri, T Chiba, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006, 441(7095): 880-884.
[96]
T Hara, K Nakamura, M Matsui, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006, 441(7095): 885-889.
Journal of Neurorestoratology
Pages 207-222
Cite this article:
Zhang Z, Zhang S, Lui CN-P, et al. Traditional Chinese medicine-based neurorestorative therapy for Alzheimer’s and Parkinson’s disease. Journal of Neurorestoratology, 2019, 7(4): 207-222. https://doi.org/10.26599/JNR.2019.9040026

1216

Views

63

Downloads

20

Crossref

17

Web of Science

0

Scopus

Altmetrics

Received: 21 October 2019
Revised: 03 December 2019
Accepted: 30 December 2019
Published: 17 January 2020
© The authors 2019

This article is published with open access at http://jnr.tsinghuajournals.com

Return